Susan G. Komen Career Catalyst Research (CCR) Grants foster
promising breast cancer researchers who are in the early stages of their
faculty careers by providing support for up to three years of “protected time”
for research career development under the guidance of a Mentor Committee. Komen
seeks to support those who will emerge as the next key leaders in the fight
against breast cancer.
Research projects must be hypothesis-driven, breast
cancer-focused studies. They may be considered basic, translational, clinical
and/or population science in nature and should align with Komen’s research
priorities and mission to save lives from breast cancer. Komen’s research
priorities are conquering metastatic and aggressive breast cancers, advancing
personalized breast cancer care throughout the continuum of care, and improving
health outcomes for everyone impacted by breast cancer. Metastatic breast cancer-focused
studies may include, but are not limited to, the development of novel treatment
strategies for existing metastatic disease, strategies to prevent or arrest
metastasis and late recurrence, and innovative approaches to detect new or
recurrent metastatic breast cancer. Precision medicine-focused studies aim to
identify the most effective and appropriate strategies to treat, detect,
diagnose, and prevent disease based on genomic, biological, environmental,
economic, lifestyle and social characteristics. Applications focused on
improving health outcomes may expand our understanding of the biological,
behavioral, social, and systems contributors to disparities in breast cancer
care and outcomes and lead to new ways to treat breast cancer and/or novel
approaches to improve access and utilization of timely, high quality breast
cancer care. Applications that leverage data science (includes artificial
intelligence and other analytical methods applied to data aggregated from
multiple sources, such as electronic health records, other clinical data,
administrative databases, large data repositories, genomics and other -omics
data, etc.) are also encouraged. Applicant/PI Eligibility
- Must be nominated by the Institution’s Office of Sponsored
Programs, Grants Office or equivalent. This is a limited submission
opportunity, and the applicant/PI cannot self-nominate.
Must have a doctoral degree, such as M.D., Ph.D., Dr.P.H.,
D.O., or equivalent.
Must currently hold a full-time faculty appointment or
have a formal offer letter from the Institution that confirms position and
start date by the Application due date (October 5, 2026), documented by the Applicant/PI
Biosketch and Letter of Institutional Support.
Must not have held any faculty appointment, including
non-tenure and tenure track appointments combined, for more than a total of 6
years by the Application due date (October 5, 2026), documented by the
Applicant/PI Biosketch and Letter of Institutional Support. All positions that
are considered as “Faculty” positions by the Applicant/PI’s institution (or
prior institution) count towards the 6-year limit. This may include positions
such as Instructor, Research Fellow, or other non-tenure track faculty positions
as appropriate. All faculty positions and terms must be verified by the Letter
of Institutional Support which must also include information regarding a
pathway to independence if the applicant is not already leading their own
research lab.
Must not simultaneously hold any other Grant awarded by
Susan G. Komen.
Must not currently be or have been a Principal
Investigator on an existing NIH R01 grant or their equivalent as of the date of
Award Notification (on or around April 15, 2027).
Must conduct the proposed research and training at the
Lead Mentor’s U.S. based institution.
Must have adequate space and facilities to conduct the
proposed research and must be able to devote at least 75% of full-time effort
to breast cancer research and activities, i.e., protected research time.
Must ensure that all past and current Komen-funded Grants
are up to date and in compliance with all Komen requirements; e.g., progress
and financial report submissions, IRB (Institutional Review Boards) approvals,
etc. by the Letter of Intent due date (July 29, 2026), if applicable.
Is not required to be a U.S. citizen or permanent
resident.
May only submit ONE LOI/Application in response to this
Announcement.
Awards: Up to $150,000/year (combined direct and indirect
costs) for up to three years ($450,000)
|